Revolution Medicines FDA Early Access Approval

FDA grants early access authorization for Revolution Medicines' pancreatic cancer pill daraxonrasib for previously treated patients.
Daraxonrasib previously doubled survival versus chemotherapy in a late‑stage trial, prompting a 2.39% rise in Revolution’s share price.
The drug also under evaluation for non‑small cell lung cancer and holds an FDA priority review voucher.
Early access requires physician request; Revolution aims to open program quickly while ensuring safety and equity.